The Revolution of Targeted Therapies in Thyroid Cancer Treatment: Present and Future Promising Anti-Cancer Drugs
International Journal of Molecular Sciences · 12.04.2025 · 26 (8) · 3663
DOI: 10.3390/ijms26083663 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.04.2025. Verfasst von Sara Gil-Bernabé und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Department, Faculty of Medicine, Valladolid University, 47003 Valladolid, Spain. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Molecular Targeted Therapy, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Thyroid cancer prevalence has increased in the last few decades. Whereas the majority of well-differentiated histotypes have effective therapeutic options, the most advanced cases lacked successful treatment until recent years. Genomic alterations have emerged as targets for new anti-cancer drugs. This molecular knowledge is gradually being translated into sophisticated approaches for the stratification, management, and therapies of patients with thyroid carcinomas. The genomic characterisation of tumours in clinical assistance serves as a tool for enhancing the prognostic assessment of patients with thyroid cancer and predicting their responses to the agents. The MAPK pathway is the most predominantly activated molecular route in this cancer. Several drugs have been developed to inhibit this pathway at different levels. However, the acquired resistance that emerges is the main problem in their use. Other strategies targeting not only driver mutations but also those that confer aggressive behaviour on tumours can be potential targetable options. Due to the new therapies, patients with the most aggressive histotypes have improved survival rates. Adverse events, although manageable, have a high prevalence among the current therapies. Selective inhibitors, immunotherapies, and the combination of both will play a pivotal role in the treatment and the improvements in overall survival in thyroid cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pathology Department, Faculty of Medicine, Valladolid University, 47003 Valladolid, Spain.
- Group Pathobiology of Cancer: Inter-, Intra-Tumor Heterogeneity and Molecular Targets, Institute of Molecular Genetics and Biomedicine (IBGM), 47003 Valladolid, Spain.
ORCID-Profile: Sara Gil-Bernabé
Zitieren
APA
Gil-Bernabé, S., García-DeLaFuente, L., & García-Rostán, G. (2025). The Revolution of Targeted Therapies in Thyroid Cancer Treatment: Present and Future Promising Anti-Cancer Drugs. International Journal of Molecular Sciences, 26(8), 3663. https://doi.org/10.3390/ijms26083663
Vancouver
Gil-Bernabé S, García-DeLaFuente L, García-Rostán G. The Revolution of Targeted Therapies in Thyroid Cancer Treatment: Present and Future Promising Anti-Cancer Drugs. International Journal of Molecular Sciences. 2025;26(8):3663. doi:10.3390/ijms26083663
BibTeX
@article{GilBernab2025,
author = {Gil-Bernabé, Sara and García-DeLaFuente, Lucía and García-Rostán, Ginesa},
title = {The Revolution of Targeted Therapies in Thyroid Cancer Treatment: Present and Future Promising Anti-Cancer Drugs},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {8},
pages = {3663},
doi = {10.3390/ijms26083663}
}
EUVIMED